Camena Bioscience

Camena Bioscience is pioneering a novel enzymatic DNA synthesis platform, gSynth®, designed to produce long, complex, and accurate synthetic genes at high throughput. The technology addresses critical bottlenecks in therapeutic discovery and development, particularly for mRNA vaccines, cell and gene therapies, and CRISPR-based applications. By enabling in-house, secure, and sustainable DNA production, Camena positions itself as an enabler for the broader biotech and pharmaceutical industry, accelerating research pipelines and reducing environmental waste.

gSynth®: A TdT-free, enzymatic DNA synthesis platform comprising a proprietary enzyme mix, pure 'Addamer' reagents, the Cimban™ bioinformatics algorithm, and green chemistry processes for high-throughput production of long, complex, and accurate synthetic genes.

Camena competes with established chemical DNA synthesis giants (e.g., Twist Bioscience, IDT) and a growing cohort of enzymatic synthesis startups (e.g., Molecular Assemblies, DNA Script, Ansa Biotechnologies). Its differentiation hinges on its TdT-free approach, focus on extreme length/complexity, and green chemistry claims.